Home > Events > Precision Diagnostics Recognised Among Malaysia’s Top 10 Healthcare BioNexus Status Companies

Precision Diagnostics Recognised Among Malaysia's Top 10 Healthcare BioNexus Status Companies

Precision Diagnostics is proud to announce its recognition as one of Malaysia’s Top 10 Healthcare BioNexus Status Companies, selected from more than 600 BioNexus and Bio-based Accelerator (BBA) companies nationwide.

The recognition follows the company’s successful award of BioNexus Status by Bioeconomy Corporation, an agency under the Ministry of Science, Technology and Innovation (MOSTI). It underscores Precision Diagnostics’ commitment to advancing precision healthcare through genomic innovation, scientific excellence, and evidence-based clinical solutions.

BioNexus Status is Malaysia’s prestigious accreditation for biotechnology companies that demonstrate innovation, commercial potential, and contributions to the nation’s bioeconomy. Being recognised among the country’s Top 10 Healthcare BioNexus Status Companies further reflects Precision Diagnostics’ leadership in translating genomic science into clinically actionable healthcare solutions.

As precision medicine continues to transform healthcare globally, Precision Diagnostics remains committed to supporting healthcare professionals, hospitals, and individuals through innovative genomic services, including Pharmacogenomics (PGx), Nutrigenomics (NGx), and other precision health technologies. The company continues to collaborate with healthcare institutions, academic partners, and industry stakeholders to accelerate the adoption of precision medicine and improve patient outcomes. leadership in translating genomic science into clinically actionable healthcare solutions.

“This recognition represents an important milestone for Precision Diagnostics and reinforces our commitment to advancing precision medicine in Malaysia and beyond,” said Dr Rebecca Tay Sook Hui, Chief Executive Officer of Precision Diagnostics. “We believe genomic medicine has the potential to transform healthcare by enabling more personalised, evidence-based clinical decisions. This achievement motivates us to continue innovating and working closely with our partners to make precision healthcare more accessible to patients and healthcare providers.”
Precision Diagnostics extends its sincere appreciation to Bioeconomy Corporation, its valued partners, collaborators, healthcare professionals, and clients for their continued trust and support. The company also acknowledges the dedication and passion of its team, whose collective efforts have contributed to this significant achievement.
Looking ahead, Precision Diagnostics will continue to strengthen its role in advancing precision medicine through research, strategic collaborations, and innovative genomic solutions. The company remains committed to supporting Malaysia’s healthcare ecosystem while contributing to the global advancement of personalised healthcare.
Facebook Instagram Linkedin Youtube
Recent Events
More Events
More Blogs